fig1

MYC inhibitors in multiple myeloma

Figure 1. The response-relapse pattern in multiple myeloma patients. Monoclonal gammopathies that undergo malignant transformation are likely to respond initially to the therapy and enter in remission. However, the disease eventually relapses, and the response becomes less durable until resistance appears, resulting in relapsed refractory myeloma. Figure adapted from[6]. MGUS: Monoclonal gammopathy of undetermined significance; SMM: smoldering multiple myeloma.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/